J Coll Physicians Surg Pak. 2025 Dec;35(12):1541-1545. doi: 10.29271/jcpsp.2025.12.1541.
ABSTRACT
OBJECTIVE: To investigate the impact of plasma homocysteine (Hcy) levels on the cardiac valve calcification (CVC) in patients undergoing maintenance haemodialysis (MHD).
STUDY DESIGN: A retrospective observational analysis. Place and Duration of the Study: Department of Nephrology, Hangzhou First People's Hospital, Hangzhou, China, from May 2022 to August 2023.
METHODOLOGY: Patients undergoing MHD were classified into two groups based on the echocardiographic results: CVC group and Non-CVC group. The former had CVC, and the latter was without calcified valves. The differences in baseline data between the two groups were compared, and logistic regression analysis was employed to investigate the impact of plasma Hcy on the CVC.
RESULTS: Of the total 98 patients undergoing MHD, 64 (65.3%) had CVC, and 79 (80.6%) had hyperhomocysteinaemia. The proportion of hyperhomocysteinaemia was greater in the CVC group than in the Non-CVC group (90.6% vs. 61.8%, p = 0.001). Multivariate logistic regression indicated that, after adjusting for age, duration of dialysis, serum calcium levels, diabetes, and other variables, elevated plasma Hcy levels were independently linked to an increased risk of CVC, irrespective of whether Hcy was considered as a continuous variable (OR = 1.121, 95% CI 1.051-1.195; p <0.001) or a binary variable (OR = 5.191, 95% CI 1.379-19.54; p = 0.015).
CONCLUSION: Elevated plasma Hcy levels are independently linked to a greater risk of CVC in patients undergoing MHD.
KEY WORDS: Homocysteine, Cardiac valve calcification, Haemodialysis.
PMID:41351088 | DOI:10.29271/jcpsp.2025.12.1541